Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cetuximab + radiotherapy + cisplatin + pemetrexed in stage III unresectable non-squamous NSCLC
2009-012412-41Phase 2Completed
- Sponsor
- IFCT
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in non-small cell lung cancer (NSCLC), sponsored by IFCT. Primary endpoint: Disease Control Rate at 16 weeks. Started Nov 2009; status: completed.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-012412-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012412-41.